These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29185365)

  • 1. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
    Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
    Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
    Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators.
    Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y
    Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators.
    Li R; Ning X; He J; Lin Z; Su Y; Li R; Yin Y
    Bioorg Chem; 2021 Mar; 108():104653. PubMed ID: 33517002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
    Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
    Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
    Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
    Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
    Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
    Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationalization of the activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR.
    Kusuma M; Arora S; Kalra S; Chaturvedi A; Heuser M; Kumar R
    Curr Top Med Chem; 2021; 21(25):2258-2271. PubMed ID: 34348626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2.
    Shankar Babu M; Mahanta S; Lakhter AJ; Hato T; Paul S; Naidu SR
    PLoS One; 2018; 13(2):e0191419. PubMed ID: 29394289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
    Wang R; Zhang X; Song H; Zhou S; Li S
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4304-7. PubMed ID: 25127868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway.
    Ma Y; Yang X; Han H; Wen Z; Yang M; Zhang Y; Fu J; Wang X; Yin T; Lu G; Qi J; Lin H; Wang X; Yang Y
    Bioorg Chem; 2021 Jun; 111():104872. PubMed ID: 33838560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
    Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
    Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
    PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity of synthesized 1,4-naphthoquinone analogues on selected human cancer cell lines.
    Kishore N; Binneman B; Mahapatra A; van de Venter M; du Plessis-Stoman D; Boukes G; Houghton P; Marion Meyer JJ; Lall N
    Bioorg Med Chem; 2014 Sep; 22(17):5013-9. PubMed ID: 25059501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma.
    Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
    Eur J Med Chem; 2017 Nov; 140():84-91. PubMed ID: 28923389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells.
    Park JH; Kundu A; Lee SH; Jiang C; Lee SH; Kim YS; Kyung SY; Park SH; Kim HS
    Int J Biol Sci; 2021; 17(8):1895-1908. PubMed ID: 34131394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
    Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
    In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
    Wang X; Zhang F; Wu XR
    Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
    Zhou W; Peng Y; Li SS
    Eur J Med Chem; 2010 Dec; 45(12):6005-11. PubMed ID: 20970893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of Synthesized 1,4-Naphthoquinone Oxime Derivatives on Selected Human Cancer Cell Lines.
    Zhang Q; Dong J; Cui J; Huang G; Meng Q; Li S
    Chem Pharm Bull (Tokyo); 2018; 66(6):612-619. PubMed ID: 29863062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.